Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Cara Therapeutics Inc is a biotechnology business based in the US. Cara Therapeutics shares (CARA) are listed on the NASDAQ and all prices are listed in US Dollars. Cara Therapeutics employs 80 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$12.99|
|52-week range||$11.22 - $29.65|
|50-day moving average||$14.99|
|200-day moving average||$15.71|
|Wall St. target price||$26.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.17|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-1.29%|
|1 month (2021-09-23)||-18.04%|
|3 months (2021-07-23)||8.79%|
|6 months (2021-04-23)||-50.68%|
|1 year (2020-10-23)||-8.91%|
|2 years (2019-10-23)||-33.59%|
|3 years (2018-10-23)||18.69|
|5 years (2016-10-21)||64.22%|
Valuing Cara Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cara Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cara Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 77x. In other words, Cara Therapeutics shares trade at around 77x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cara Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.1 million.
The EBITDA is a measure of a Cara Therapeutics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$123.3 million|
|Operating margin TTM||5.54%|
|Gross profit TTM||$27.2 million|
|Return on assets TTM||2.19%|
|Return on equity TTM||4.85%|
|Market capitalisation||$659.2 million|
TTM: trailing 12 months
There are currently 2.1 million Cara Therapeutics shares held short by investors – that's known as Cara Therapeutics's "short interest". This figure is 30.2% down from 3.0 million last month.
There are a few different ways that this level of interest in shorting Cara Therapeutics shares can be evaluated.
Cara Therapeutics's "short interest ratio" (SIR) is the quantity of Cara Therapeutics shares currently shorted divided by the average quantity of Cara Therapeutics shares traded daily (recently around 813307.27969349). Cara Therapeutics's SIR currently stands at 2.61. In other words for every 100,000 Cara Therapeutics shares traded daily on the market, roughly 2610 shares are currently held short.
However Cara Therapeutics's short interest can also be evaluated against the total number of Cara Therapeutics shares, or, against the total number of tradable Cara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cara Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Cara Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0473% of the tradable shares (for every 100,000 tradable Cara Therapeutics shares, roughly 47 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cara Therapeutics.
Find out more about how you can short Cara Therapeutics stock.
We're not expecting Cara Therapeutics to pay a dividend over the next 12 months.
Cara Therapeutics's shares were split on a 1:2 basis on 15 January 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cara Therapeutics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Cara Therapeutics shares which in turn could have impacted Cara Therapeutics's share price.
Over the last 12 months, Cara Therapeutics's shares have ranged in value from as little as $11.22 up to $29.6473. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cara Therapeutics's is 1.1302. This would suggest that Cara Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cara Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.